|Articles|May 8, 2018
The Missing Link in Amazon’s Healthcare Takeover
Author(s)Michelle Maskaly
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries.
Advertisement
John Cervione, managing partner of Blue Fin Group, talks briefly about Amazon’s foray into the healthcare and pharma industries, talks about what they are doing now, and the key element that is missing. His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5